Division of Infectious Diseases, Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States of America.
Department of Pediatrics, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States of America.
PLoS One. 2024 Sep 25;19(9):e0310980. doi: 10.1371/journal.pone.0310980. eCollection 2024.
SARS-CoV-2 infection during pregnancy was associated with maternal mortality and adverse birth outcomes in the pre-Omicron era, including a stillbirth rate of 5.6% in Botswana. We re-evaluated these outcomes in the Tsepamo Study during the Omicron era. We assessed maternal mortality and adverse birth outcomes for all singleton pregnancies from mid-November 2021 (the start of the Omicron era) to mid-August 2022 at nine Tsepamo sites, among individuals with documented SARS-CoV-2 screening PCR or antigen tests and known HIV status. Of 9,705 women routinely screened for SARS-CoV-2 infection at delivery (64% of deliveries at these sites), 373 (3.8%) tested positive. Women with HIV were as likely to test positive for SARS-CoV-2 (77/1833, 4.2%) as women without HIV (293/6981, 4.2%) (p = 1.0). There were 5 recorded maternal deaths (0.03%), one occurring in a woman with a positive SARS-CoV-2 test result. In contrast, maternal mortality was 3.7% and 0.1% in those with and without SARS-CoV-2, respectively, during the pre-Omicron era. In the Omicron era, there were no differences among infants exposed or unexposed to SARS-CoV-2 in overall adverse birth outcomes (28.1% vs 29.6%; aRR 1.0, 95%CI 0.8-1.1), severe adverse birth outcomes (11.9 vs 10.6%; aRR 1.1, 95%CI 0.8-1.5), preterm delivery (15.1% vs 14.9%; aRR 1.0, 95%CI 0.8-1.3), or stillbirth (1.9% vs 2.3%; aRR 0.8, 95%CI 0.4-1.7). Adverse outcomes among those exposed to both HIV and SARS-CoV-2 were similar to those exposed to HIV alone (31.2% vs. 33.1%; aRR 0.9, 95%CI 0.6-1.3; p = 0.5). Maternal mortality was far lower in Botswana during the Omicron era than in the pre-Omicron era, and adverse birth outcomes were no longer significantly impacted by exposure to SARS-CoV-2 either overall or with HIV co-exposure. Increased population immunity to SARS-CoV-2, less stress on the hospital systems in the Omicron era, and possible differences in viral pathogenicity may combine to explain these findings.
在奥密克戎时代,SARS-CoV-2 感染与孕产妇死亡率和不良出生结局相关,博茨瓦纳的死产率为 5.6%。我们在奥密克戎时代重新评估了泰普阿莫研究中的这些结果。我们评估了 9 个泰普阿莫地点在 2021 年 11 月中旬(奥密克戎时代开始)至 2022 年 8 月中旬期间所有单胎妊娠的孕产妇死亡率和不良出生结局,这些妊娠都进行了 SARS-CoV-2 筛查 PCR 或抗原检测,并已知 HIV 状况。在常规分娩时筛查 SARS-CoV-2 感染的 9705 名妇女(这些地点分娩的 64%)中,有 373 名(3.8%)检测呈阳性。HIV 阳性妇女与 HIV 阴性妇女(77/1833,4.2%)检测 SARS-CoV-2 阳性的可能性相同(293/6981,4.2%)(p=1.0)。记录了 5 例孕产妇死亡(0.03%),其中一例发生在 SARS-CoV-2 检测结果阳性的妇女中。相比之下,在奥密克戎时代,SARS-CoV-2 阳性组和阴性组的孕产妇死亡率分别为 3.7%和 0.1%。在奥密克戎时代,暴露于 SARS-CoV-2 或未暴露于 SARS-CoV-2 的婴儿在总体不良出生结局(28.1%比 29.6%;aRR1.0,95%CI0.8-1.1)、严重不良出生结局(11.9%比 10.6%;aRR1.1,95%CI0.8-1.5)、早产(15.1%比 14.9%;aRR1.0,95%CI0.8-1.3)或死产(1.9%比 2.3%;aRR0.8,95%CI0.4-1.7)方面没有差异。同时暴露于 HIV 和 SARS-CoV-2 的婴儿的不良结局与单独暴露于 HIV 的婴儿相似(31.2%比 33.1%;aRR0.9,95%CI0.6-1.3;p=0.5)。在奥密克戎时代,博茨瓦纳的孕产妇死亡率远低于奥密克戎前时代,而且暴露于 SARS-CoV-2 不再显著影响总体或与 HIV 同时暴露的不良出生结局。SARS-CoV-2 人群免疫力的增加、奥密克戎时代医院系统压力的减轻以及病毒致病性的差异可能共同导致了这些发现。